Home  |  Contact

Cellosaurus OVTOKO (CVCL_3117)

[Text version]

Cell line name OVTOKO
Accession CVCL_3117
Resource Identification Initiative To cite this cell line use: OVTOKO (RRID:CVCL_3117)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Doubling time: 70 hours (PubMed=7535723; PubMed=9328139; PubMed=11121861).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Genome sequenced.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Genome ancestry Source: PubMed=30894373

Origin% genome
African0
Native American0
East Asian, North82.47
East Asian, South16.63
South Asian0
European, North0
European, South0.89
Disease Ovarian clear cell adenocarcinoma (NCIt: C40078)
Derived from metastatic site: Spleen.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 78Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; JCRB; PubMed=25877200; PubMed=30485824

Markers:
AmelogeninX
CSF1PO12
D3S135815
D5S81811,12
D7S8209,10
D8S117910,14
D13S3178,12
D16S53911,12
D18S5119
D21S1129,31
FGA21,23
Penta D9,10
Penta E14
TH016,9.3
TPOX8,12
vWA14,17

Run an STR similarity search on this cell line
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=7535723; DOI=10.1006/gyno.1995.1097
Gorai I., Nakazawa T., Miyagi E., Hirahara F., Nagashima Y., Minaguchi H.
Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties.
Gynecol. Oncol. 57:33-46(1995)

PubMed=9328139; DOI=10.1038/bjc.1997.471
Yanagibashi T., Gorai I., Nakazawa T., Miyagi E., Hirahara F., Kitamura H., Minaguchi H.
Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20.
Br. J. Cancer 76:829-835(1997)

PubMed=11121861; DOI=10.1016/S0304-3835(00)00605-4
Ohta I., Gorai I., Miyamoto Y., Yang J., Zheng J.-H., Kawata N., Hirahara F., Shirotake S.
Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells.
Cancer Lett. 162:39-48(2001)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567
Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K., Hirohashi S., Inazawa J., Imoto I.
Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Cancer Res. 67:7095-7105(2007)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22705003; DOI=10.1016/j.humpath.2012.03.011
Rahman M., Nakayama K., Rahman M.T., Nakayama N., Ishikawa M., Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih I.-M., Miyazaki K.
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Hum. Pathol. 43:2197-2206(2012)

PubMed=23430509; DOI=10.1007/s13577-013-0062-y
Itamochi H., Kato M., Nishimura M., Oumi N., Oishi T., Shimada M., Sato S., Naniwa J., Sato S., Nonaka M., Kudoh A., Terakawa N., Kigawa J., Harada T.
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.
Hum. Cell 26:121-127(2013)

PubMed=23839242; DOI=10.1038/ncomms3126
Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.
Evaluating cell lines as tumour models by comparison of genomic profiles.
Nat. Commun. 4:2126-2126(2013)

PubMed=24023729; DOI=10.1371/journal.pone.0072162
Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
Type-specific cell line models for type-specific ovarian cancer research.
PLoS ONE 8:E72162-E72162(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096
Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R., Easwaran H., Baylin S.B., Slamon D., Velculescu V.E., Scharpf R.B.
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Cell Rep. 25:2617-2633(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

Cross-references
Cell line collections JCRB; JCRB1048
JCRB; NIHS0301 - Discontinued
JCRB; NIHS0343 - Discontinued
Cell line databases/resources CCLE; OVTOKO_OVARY
Cell_Model_Passport; SIDM00425
CGH-DB; 331-2
Cosmic-CLP; 1298365
DepMap; ACH-000663
GDSC; 1298365
LINCS_LDP; LCL-1528
Ontologies BTO; BTO:0003499
EFO; EFO_0006728
Biological sample resources BioSample; SAMN03472861
BioSample; SAMN10987767
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM459732
GEO; GSM659399
GEO; GSM827253
GEO; GSM887490
GEO; GSM888572
GEO; GSM1176282
GEO; GSM1670325
Other Wikidata; Q54937039
Polymorphism and mutation databases Cosmic; 1223318
Cosmic; 1328067
Cosmic; 1434895
Cosmic; 1708379
Cosmic; 1889263
Cosmic; 2074248
Cosmic; 2482705
IARC_TP53; 30142
LiGeA; CCLE_135
Entry history
Entry creation04-Apr-2012
Last entry updated05-Jul-2019
Version number25